Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status

This publication has 31 references indexed in Scilit:

• Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
  BMC Pulmonary Medicine, 2011
• Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD Patients
  Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
• Effects of extra‐fine inhaled beclomethasone/formoterol on both large and small airways in asthma
  Allergy, 2010
• “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
  Respiratory Medicine, 2009
• Systemic Exposure and Implications for Lung Deposition with an Extra-Fine Hydrofluoroalkane Beclometasone Dipropionate/Formoterol Fixed Combination
  Clinical Pharmacokinetics, 2009
• Asthma control in Europe: A real-world evaluation based on an international population-based study
  Journal of Allergy and Clinical Immunology, 2007
• Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology
  Pulmonary Pharmacology & Therapeutics, 2007
• A Randomized, Double-Blind, Double-Dummy, Single-Dose, Crossover Trial Evaluating the Efficacy and Safety Profiles of Two Dose Levels (12 and 24 μg) of Formoterol-HFA (pMDI) vs. Those of a Dose Level (24 μg) of Formoterol-DPI (Foradil®/Aerolizer™) and of Placebo (pMDI or Aerolizer) in Moderate to Severe Asthmatic Patients
  Respiration, 2005
• A Randomized, Double-Blind, Double-Dummy, Single-Dose, Efficacy Crossover Trial Comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (AerolizerTM) and Placebo (pMDI or AerolizerTM) in Asthmatic Patients
  Respiration, 2005
• Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo‐controlled, crossover study
  British Journal of Clinical Pharmacology, 2004